Sign in

INFU on NYSE

InfuSystem Holdings, Inc

American surgical and medical instruments and apparatus company2

In its 2026 annual report the company says: “InfuSystem Holdings, Inc. is a Delaware corporation. We are a leading national healthcare service provider, facilitating outpatient care for Durable Medical Equipment (DME) manufacturers and healthcare providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site healthcare providers.”5 It is headquartered in Rochester Hills, United States.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Neuronetics, Inc., Xtant Medical (United States) or Heartflow, Inc., or pick any stock.

  • TickerINFU on NYSE2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersRochester Hills, United States2
  • Incorporated inDE3
  • Business address3851 West Hamlin Road, Rochester Hills, Mi 483093
  • Filer categoryAccelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300F58N8PHJ4QUI592
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O REGISTERED AGENT SOLUTIONS, INC., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 40118412

See how the biggest companies compare on our leaderboards

InfuSystem Holdings, Inc. ("we," "us," "our" or the "Company") is a Delaware corporation. Formed in 2005, the Company operates through its subsidiary InfuSystem, Inc., a Delaware corporation ("InfuSystem" or "ISI").5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

56.0%Gross margin6
8.3%Operating margin6
4.6%Net margin6
6.4%Revenue growth, 20256
11.6%Return on equity6
0.34×Debt to equity6
$23.8MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Patient Services And Device Solutions brought in 44% of the revenue InfuSystem Holdings, Inc broke down this way in fiscal 2025.

  1. Patient Services And Device Solutions$113.1M644%up 6% from 2024
  2. Patient Services$78.2M631%up 7% from 2024
  3. Device Solutions$64.1M625%up 4% from 2024
Business segments by year
Business segments20242025
Patient Services And Device Solutions$106.3M$113.1M
Patient Services$72.8M$78.2M
Device Solutions$61.7M$64.1M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue44¢$63.1M
  • Other costs49¢$69.7M
  • Income tax3¢$4.0M
  • Profit5¢$6.6M

Out of $143.4M in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending2¢$560.0K
  • Share buybacks40¢$9.9M
  • Kept or used elsewhere57¢$14.0M

Out of $24.4M of cash from operations.6

Financial statements

Revenue789106$143.4M in 2025+77% since 2019
0$50.0M$100.0M$150.0M2019: $81.1M$81.1M20192020: $97.4M$97.4M2020+20%2021: $102.4M$102.4M2021+5%2022: $109.9M$109.9M2022+7%2023: $125.8M$125.8M2023+14%2024: $134.9M$134.9M2024+7%2025: $143.4M$143.4M2025+6%
Gross profit789106$80.3M in 2025+71% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $46.9M$46.9M20192020: $58.8M$58.8M2020+25%2021: $58.5M$58.5M2021−0%2022: $60.6M$60.6M2022+3%2023: $63.1M$63.1M2023+4%2024: $70.4M$70.4M2024+12%2025: $80.3M$80.3M2025+14%
Operating income789106$11.9M in 2025+238% since 2019
0$5.0M$10.0M$15.0M2019: $3.5M$3.5M20192020: $8.8M$8.8M2020+150%2021: $2.8M$2.8M2021−68%2022: $1.7M$1.7M2022−41%2023: $4.1M$4.1M2023+147%2024: $6.9M$6.9M2024+69%2025: $11.9M$11.9M2025+73%
Net income789106$6.6M in 2025+387% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $1.4M$1.4M20192020: $17.3M$17.3M2020+1173%2021: $1.4M$1.4M2021−92%2022: $18.0K$18.0K2022−99%2023: $872.0K$872.0K2023+4744%2024: $2.3M$2.3M2024+169%2025: $6.6M$6.6M2025+183%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Net revenues$143.4M$134.9M
Cost of revenues$63.1M$64.5M
Gross profit$80.3M$70.4M
Amortization of intangibles$920.0K$991.0K
Selling and marketing$10.5M$11.3M
General and administrative$57.0M$51.2M
Total selling, general and administrative$68.4M$63.5M
Operating income$11.9M$6.9M
Interest expense-$1.3M-$1.8M
Other income (expense)$2.0K-$55.0K
Income (Loss) before income taxes$10.6M$5.1M
Provision for income taxes-$4.0M-$2.7M
Basic (in dollars per share)$0.32$0.11
Diluted (in dollars per share)$0.31$0.11
Basic (in shares)20.7M shares21.3M shares
Diluted (in shares)21.1M shares21.7M shares
Net income$6.6M$2.3M
Unrealized gain (loss) on hedges-$733.0K$40.0K
(Provision for) benefit from income tax on unrealized hedge gain (loss)$179.0K-$9.0K
Other comprehensive income (loss)-$554.0K$31.0K
Net comprehensive income$6.1M$2.4M

Compare InfuSystem Holdings, Inc with another company

Corporate structure

InfuSystem Holdings, Inc sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of InfuSystem Holdings, Inc

  • BlackRock Filed SCHEDULE 13G on InfuSystem Holdings, Inc, latest Jul 28, 2026 (3 filings since Jan 29, 2024)
  • Minerva Advisors LLC Filed SCHEDULE 13G/A on InfuSystem Holdings, Inc, latest Feb 17, 2026 (2 filings since Dec 3, 2025)
  • AWM Investment Company, Inc. Filed SCHEDULE 13G/A on InfuSystem Holdings, Inc, latest Nov 13, 2025 (5 filings since Feb 14, 2023)
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on InfuSystem Holdings, Inc, latest Jul 29, 2025 (2 filings since Feb 13, 2024)
  • SANSONE ADVISORS, LLC Filed SCHEDULE 13D/A on InfuSystem Holdings, Inc, latest Jan 22, 2025 (4 filings since Nov 29, 2023)
  • Scott Shuda Filed SC 13D/A on InfuSystem Holdings, Inc, latest Dec 6, 2024 (2 filings since Mar 28, 2023)
  • Acuitas Investments, LLC Filed SCHEDULE 13G/A on InfuSystem Holdings, Inc, latest Nov 7, 2024 (3 filings since Jan 12, 2023)
  • InfuSystem Holdings, Inc Rochester Hills, Michigan, United States
    • InfuSystem, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What InfuSystem Holdings, Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$06 Dec 31, 2025$06 Dec 31, 2024
Property and equipment, before depreciation$11.5M6 Dec 31, 2025$11.2M6 Dec 31, 2024+3.1%
Accumulated depreciation$8.2M6 Dec 31, 2025$7.1M6 Dec 31, 2024+14.2%
Property and equipment, net$3.4M6 Dec 31, 2025$4.0M6 Dec 31, 2024−16.7%
Operating-lease assets (leased space)$4.2M6 Dec 31, 2025$5.4M6 Dec 31, 2024−22.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.2M6 Dec 31, 2025$527.0K6 Dec 31, 2024+504.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$3.7M6 Dec 31, 2025$3.7M6 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$6.9M6 Dec 31, 2025$6.5M6 Dec 31, 2024+6.4%
Indefinite-lived intangibles (excluding goodwill)$2.0M6 Dec 31, 2025$2.0M6 Dec 31, 20240%
Accumulated amortization$47.0M6 Dec 31, 2025$46.1M6 Dec 31, 2024+2.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$5.4M6 Dec 31, 2025$6.5M6 Dec 31, 2024−17.4%

Properties, in its own words

We do not own any real property. We lease office and warehouse space at the following locations:

City · State/Country

The rest of Item 2

Rochester Hills · Michigan

Lenexa · Kansas

Canton · Massachusetts

Bakersfield · California

Santa Fe Springs · California

Dallas · Texas

Mississauga · Ontario, Canada

We believe that such office and warehouse space is suitable and adequate for our business. All of our facilities are utilized to support both of our segments.

Item 2 of the 10-K filed Feb 27, 2026.5

Leadership

Who has led InfuSystem Holdings, Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven Watkins2007–2009
  2. Sean McDevitt2010–2012
  3. Dilip Singh2012
  4. Eric K. Steen2013–2017
  5. Richard Dilorio2017–2025
  6. Carrie Lachance2025–now

Chair

  1. Ryan J. Morris2012–2014

President

  1. Eric K. Steen2016–2017
  2. Richard Dilorio2019–2022
  3. Carrie Lachance2021–now

Chief financial officer

  1. Erin Suzanne Enright2006–2007
  2. Sean Whelan2007–2010
  3. James M. Froisland2010–2011
  4. Jonathan P. Foster2012–2015
  5. Gregory Schulte2018–2019
  6. Wesley W. Winnekins2020
  7. Barry G. Steele2020–now

Chief operating officer

  1. Janet Skonieczny2013–2017
  2. Carrie Lachance2019–now
2010201520202025
Board members and other officers (41)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • InfuSystem, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • HAPC, Inc.Apr 26, 2006 to Oct 30, 20073
  • Healthcare Acquisition Partners Corp.Oct 14, 2005 to Apr 25, 20063

Timeline

  1. Sep 17, 20268-K Regulation FD disclosure69
  2. Aug 4, 20268-K Results of operations70
  3. Aug 4, 20268-K Regulation FD disclosure71
  4. Jul 28, 20268-K Regulation FD disclosure72
  5. May 18, 20268-K Regulation FD disclosure73
  6. May 14, 20268-K Executive or director change74
  7. May 12, 20268-K Executive or director change; Shareholder vote75
  8. May 7, 20268-K Results of operations76
  9. Apr 30, 20268-K Regulation FD disclosure77
  10. Mar 19, 20268-K Change of auditor78
  11. Mar 16, 20268-K Regulation FD disclosure79
  12. Feb 27, 20268-K Regulation FD disclosure80
  13. Sep 25, 2025New chief executive Carrie Lachance becomes CEO14
  14. Dec 12, 2017New chief executive Richard Dilorio becomes CEO15
  15. Apr 1, 2013New chief executive Eric K. Steen becomes CEO16
  16. Apr 26, 2012New chief executive Dilip Singh becomes CEO17
  17. Dec 7, 2010New chief executive Sean McDevitt becomes CEO18
  18. Nov 21, 2007New chief executive Steven Watkins becomes CEO19
  19. Aug 15, 2005Founded InfuSystem Holdings, Inc is founded2

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.11 a share, on Nov 4, 2025.81

When it reported results

  1. Aug 4, 2026Reported quarterly or annual results70
  2. May 7, 2026Reported quarterly or annual results76
  3. Feb 24, 2026Reported quarterly or annual results82
  4. Nov 4, 2025Reported quarterly or annual results83
  5. Aug 5, 2025Reported quarterly or annual results84
  6. May 8, 2025Reported quarterly or annual results85
  7. Mar 4, 2025Reported quarterly or annual results86
  8. Nov 7, 2024Reported quarterly or annual results87

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

296 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 102 major events, 137 insider forms, 21 large holders, 16 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Sep 17, 20268-K EDGAR
  3. Sep 11, 20264 EDGAR
  4. Aug 4, 202610-Q EDGAR
  5. Aug 4, 20268-K EDGAR
  6. Aug 4, 20268-K EDGAR
  7. Jul 28, 2026SCHEDULE 13G EDGAR
  8. Jul 28, 20268-K EDGAR
  9. May 19, 20264 EDGAR
  10. May 19, 20264 EDGAR
  11. May 19, 20264 EDGAR
  12. May 19, 20264 EDGAR
  13. May 18, 20268-K EDGAR
  14. May 18, 2026S-8 EDGAR
  15. May 14, 20264 EDGAR
  16. May 14, 20264 EDGAR
  17. May 14, 20264 EDGAR
  18. May 14, 20264 EDGAR
  19. May 14, 20264 EDGAR
  20. May 14, 20264 EDGAR

The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

68 open-market trades by officers, directors and large owners since October 2021: 21 buys and 47 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 11, 2026Lachance CarriePresident and CEOBuy1,000$8.46$8.5KForm 4
May 8, 2026GENDRON PAUL ANDREWDirectorBuy5,000$8.88$44.4KForm 4
May 8, 2026Lachance CarriePresident and CEOBuy2,000$8.83$17.7KForm 4
May 8, 2026Steele Barry GExecutive VP and CFOBuy7,000$8.71$61.0KForm 4
Mar 2, 2026Steele Barry GExecutive VP and CFOBuy2,064$9.16$18.9KForm 4
Aug 22, 2025Shuda ScottDirectorSale5,752$9.67$55.6KForm 4
May 28, 2025Eichenbaum Kenneth D.DirectorBuy2,000$5.18$10.4KForm 4
May 19, 2025Hundzinski Ronald TDirectorBuy5,000$6.09$30.4KForm 4
May 16, 2025Lachance CarriePresident and CEOBuy1,967$6.10$12.0KForm 4
May 15, 2025Lachance CarriePresident and CEOBuy1,165$6.01$7.0KForm 4
May 14, 2025Steele Barry GExecutive VP and CFOBuy3,000$5.76$17.3KForm 4
Nov 27, 2024Dilorio RichardChief Executive OfficerSale5,398$8.87$47.9KForm 4
Nov 26, 2024Dilorio RichardChief Executive OfficerSale14,602$8.91$130.1KForm 4
Nov 25, 2024Dilorio RichardChief Executive OfficerSale20,000$9.32$186.4KForm 4
Sep 23, 2024Eichenbaum Kenneth D.DirectorBuy4,000$5.89$23.6KForm 4
May 23, 2024BOYD RALPH F JRDirectorBuy4,000$7.13$28.5KForm 4
May 22, 2024HUSS BEVERLY ADirectorBuy4,300$6.86$29.5KForm 4
May 21, 2024Chupa AddamExecutive VP and CIOBuy1,000$6.67$6.7KForm 4
May 20, 2024Steele Barry GExecutive VP and CFOBuy3,000$6.47$19.4KForm 4
May 20, 2024Funke JerodEVP-Chief HR OfficerBuy1,000$6.39$6.4KForm 4

All 68 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Carrie Lachance49$478.9K$2.9M95
2025Barry Steele55$432.6K$1.5M95
2025Richard DiIorio$278.7K$1.3M95
2025Jerod Funke51$373.1K$1.1M95
2024Former ChiefExecutive Officer$630.0K$2.5M95
2024Chief Executive Officer$430.5K$1.3M95
2024Executive VicePresident and Chief Financial Officer$420.0K$1.3M95
2024Executive Vice PresidentChief Human Resources Officer$358.8K$936.4K95

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.1,585,415$15.3M0.0%+968,829
Minerva Advisors LLC1,348,617$13.0M8.2%+144,512
First Eagle Investment Management, LLC1,240,000$12.0M0.0%+518,629
Punch & Associates Investment Management, Inc.834,750$8.1M0.4%−3,175
Vanguard Capital Management LLC790,775$7.6M0.0%−69,488
Heartland Advisors Inc700,000$6.8M0.3%+190,000
American Century Companies Inc675,028$6.5M0.0%+202,007
Dimensional Fund Advisors LP599,289$5.8M0.0%+5,001
Renaissance Technologies LLC543,009$5.2M0.0%−23,800
Geode Capital Management, LLC496,059$4.8M0.0%+277,614
Diamond Hill Capital Management, LLC (Investment Advisor)489,017$4.7M0.0%New
Meros Investment Management, LP468,934$4.5M1.4%−474
Hillsdale Investment Management Inc.424,473$4.1M0.1%−27,900
Arrowstreet Capital, Limited Partnership368,712$3.6M0.0%No change
White Pine Capital LLC225,634$2.2M0.5%−20,393
State Street Corp212,571$2.1M0.0%+114,500
Panagora Asset Management Inc194,922$1.9M0.0%+112,134
Teton Advisors, LLC185,000$1.8M1.0%No change
Expect Equity LLC184,819$1.8M1.1%+103,873
North Star Investment Management Corp.182,000$1.8M0.1%No change
Citadel Advisors LLC180,650$1.7M0.0%+10,696
Northern Trust Corp153,506$1.5M0.0%+96,695
Two Sigma Investments, LP148,347$1.4M0.0%−37,064
Gabelli Funds LLC145,085$1.4M0.0%−3,400
Vanguard Fiduciary Trust Co141,134$1.4M0.0%+19,146

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How InfuSystem Holdings, Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInfuSystem Holdings, Inc1
  • CIK0001337013
  • Employer ID (EIN)20-33414055
  • Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address3851 West Hamlin Road, Rochester Hills, MI 483091
  • Phone(248) 291-12101
  • Shares outstanding19,917,181 as of Jul 31, 202612
  • Public float$122.3M as of Jun 30, 20255
  • AuditorDeloitte & Touche LLP, Detroit, Michigan PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
  • On EDGAR sinceOct 14, 20051
  • Filings1,226 in all: 4 (427), 8-K (350), 10-Q (62), SC 13G/A (62), 3 (58), DEFA14A (41), SC 13D/A (29), SC 13G (29)1
    All 44 form types

    10-K (20), DEF 14A (19), S-8 (14), SC 13D (10), UPLOAD (10), DFAN14A (9), 10-K/A (8), 8-K/A (7), S-1/A (7), SCHEDULE 13G/A (7), 10-Q/A (5), 144 (4), ARS (4), DEFC14A (4), NT 10-Q (4), PREC14A (4), PRER14A (4), CORRESP (3), 4/A (2), 8-A12G (2), NT 10-K (2), PRE 14A (2), S-1 (2), SC TO-I/A (2), SCHEDULE 13G (2), 424B1 (1), 424B4 (1), 5 (1), 8-A12B (1), CERTNYS (1), CT ORDER (1), EFFECT (1), PREC14C (1), PREM14A (1), SC TO-I (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2026
    Quarterly report (10-Q) Aug 4, 2026
    Proxy statement (DEF 14A) Apr 10, 2026
    Latest 8-K (8-K) Sep 17, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareINFUNYSE American LLC

From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks InfuSystem Holdings, Inc names in Item 1A of its 10-K filed Feb 27, 2026: 42 risks under these headings, as written.5

  • Any change in the overall healthcare reimbursement system may adversely impact our business.
  • Our business is substantially dependent on estimates of collectible revenue from third-party reimbursement.
  • The loss of a relationship with one or more third-party payers could negatively impact our business.
  • Any federal government shutdown may adversely impact our business.
  • Payer concentration may adversely impact our business.
  • Increased focus on early detection and diagnostics may adversely affect our business.
  • If future clinical studies demonstrate that oral medications or other therapies that do not use our electronic ambulatory pumps are at least as effective as continuous infusion therapy, our business could be adversely affected.
  • Our success is impacted by the availability of the chemotherapy drugs that are used in our continuous infusion pump systems.
  • We are dependent on our Medicare Supplier Number.
  • The impact of actual or perceived U.S. healthcare reform legislation on us remains uncertain.
  • We rely on independent suppliers for our products. Any delay or disruption in the supply of products, particularly our supply of electronic ambulatory pumps, may negatively impact our operations.
  • We face periodic reviews and billing audits from governmental and private payers and these audits could have adverse results that may negatively impact our business.
The other 30 risks
  • Our failure to maintain controls and processes over billing and collecting could have a negative impact on our Consolidated Financial Statements.
  • State licensure laws for Durable Medical Equipment suppliers are subject to change. If we fail to comply with any state laws, we will be unable to operate as a Durable Medical Equipment supplier in such state and our business operations will be adversely affected.
  • Our customer concessions may not be adequate to cover actual losses.
  • Our growth strategy includes expanding into treatment for cancers other than colorectal cancer. There can be no assurance that continuous infusion-based regimens for these other cancers will become standards of care for large numbers of patients or that we will be successful in penetrating these different markets.
  • The industry in which we operate is intensely competitive and ever-changing. If we are unable to successfully compete with our competitors, our business operations may suffer.
  • Our industry is dependent on regulatory guidelines that affect our billing practices. If our competitors do not comply with these regulatory guidelines, our business could be adversely affected.
  • Although we do not manufacture the products we distribute, if one of the products distributed by us proves to be defective or is misused by a healthcare practitioner or patient, we may be subject to liability that could adversely affect our financial condition and results of operations.
  • We have in the past, and in the future intend to pursue growth opportunities through strategic alliances, joint ventures and strategic acquisitions, which may divert our management's attention, and we may be unable to achieve the expected benefits of such alliances, joint ventures or acquisitions.
  • If we are unable to support increased operations or personnel, our future growth and business could suffer.
  • We may be unable to maintain adequate working relationships with healthcare professionals.
  • If we fail to comply with applicable governmental or accrediting bodies’ regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
  • Failure to protect our intellectual property could substantially harm our business and operating results.
  • Covenants in our current and any future debt agreements restrict our business.
  • Economic uncertainty or deterioration or geopolitical instability could adversely affect us.
  • Changes in tax laws or challenges to our tax positions could adversely affect our business, results of operations and financial condition.
  • The value of our net operating loss carryforwards may become impaired if we do not generate sufficient future taxable income required to utilize all or a portion of our net operating loss carryforwards prior to their expiration.
  • The market price of our common stock has been, and is likely to remain, volatile, subject to low trading volume and may decline in value.
  • We do not pay dividends and this may negatively affect the price of our stock.
  • Restricted stock awards, performance-based restricted stock units and the exercise of stock options may depress our stock price and may result in dilution to our common stockholders.
  • We may be subject to limitations on net operating loss carryforwards and certain built-in losses following an ownership change.
  • GENERAL RISK FACTORS
  • A material weakness in our internal control over financial reporting could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations.
  • Any future pandemic, epidemic or outbreak of any highly infectious disease could cause disruptions in the U.S., regional and global economies and could materially and adversely impact our business, financial condition and results of operations and the business, financial condition and results of operations.
  • We may become subject to legal and regulatory proceedings that could have a material adverse impact on our business, results of operations and financial condition.
  • We do not collect sales or consumption taxes in some jurisdictions.
  • If we are unsuccessful in our efforts to implement and support information technology improvements or respond to technological changes, our growth, prospects and results of operations could be adversely affected.
  • Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.
  • Technological interruptions or the efficiency of our technology solutions could damage our reputation and brand and adversely affect our results of operations.
  • Failure to maintain the privacy and security of our customer, third-party payer, employee, supplier, or Company information could result in substantial costs or subject us to litigation, enforcement actions, and reputational damage.
  • Natural disasters, pandemics, acts of war or terrorism and other external events could significantly impact our business.
  • We are dependent upon executive officers and other key personnel. The loss of any of our executive officers or other key personnel could reduce our ability to manage our businesses and achieve our business plan, which could cause our sales to decline and our operating results and cash flows to suffer.

Legal proceedings

We are subject to certain claims and lawsuits in the ordinary course of business, the outcome of which cannot be determined at this time. In the opinion of management, any liability we might incur upon the resolution of these claims and lawsuits will not, in the aggregate, have a material adverse effect on our consolidated financial position or results of operations.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95